Clinical investigation of botulinum toxin (prabotulinumtoxin A) for bruxism related to masseter muscle hypertrophy: A prospective study
- Authors
- Jung, Bok Ki; Park, Hojin; Cheon, Young Woo; Yun, In Sik; Choi, Jong-Woo; Kim, Han Jo; Lee, Mu Young; Kang, Byeong Su; Kang, Tae Jo
- Issue Date
- May-2023
- Publisher
- CHURCHILL LIVINGSTONE
- Keywords
- Botulinum toxins; Bruxism; Masseter muscle
- Citation
- JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, v.51, no.5, pp.332 - 337
- Journal Title
- JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY
- Volume
- 51
- Number
- 5
- Start Page
- 332
- End Page
- 337
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/89037
- DOI
- 10.1016/j.jcms.2023.05.005
- ISSN
- 1010-5182
- Abstract
- This study aims to confirm the effectiveness and safety of a prabotulinumtoxin type A (praBTX-A) injection in patients with bruxism and masseter hypertrophy. The study included patients who ground or clenched their teeth while sleeping and had computed tomography (CT) scans that showed a maximum thickness of the masseter muscle of 15 mm or more. The praBTX-A was administered bilaterally into the masseter muscles; 15 U/side for group 1, 25 U/side for group 2, and 35 U/side for group 3. CT scans and bruxism questionnaires were conducted before and eight weeks after the injection. Thirty-seven patients were enrolled, but three dropped out due to loss of follow-up. After injection, masseter thickness decreased to 15.1 & PLUSMN; 2.0 mm for group 1, 14.3 & PLUSMN; 2.9 mm for group 2, and 13.4 & PLUSMN; 1.8 mm for group 3 (p = 0.043). Group 3 showed a statistically significant lower masseter thickness compared to group 1 (p = 0.039). Both subjective and objective frequencies of bruxism decreased for all groups, but there were no significant differences in either subjective (p = 0.396) or objective frequencies (p = 0.87) between the groups after the injection. The results of this study suggest that praBTX-A injection is a safe and effective treatment for bruxism and masseter hypertrophy. A dosage of 35 IU/side can effectively decrease masseter thickness and relieve bruxism symptoms. Even the minimum dosage of 15 IU/side can contribute to improvements in bruxism symptoms. This investigation provides valuable information for managing bruxism that is associated with hypertrophic masseter muscles. & COPY; 2023 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/89037)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.